We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$275M
AUM Growth
-$121M
Cap. Flow
-$91.5M
Cap. Flow %
-33.22%
Top 10 Hldgs %
43.72%
Holding
87
New
14
Increased
18
Reduced
10
Closed
32

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$11.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$7.62M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$6.89M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$6.84M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$6.59M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$7.5M
2
BBIO icon
BridgeBio Pharma
BBIO
+$6.79M
3
XLRN
Acceleron Pharma
XLRN
+$6.08M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.72M
5
TVTX icon
Travere Therapeutics
TVTX
+$4.22M

Sector Composition

Rank Sector Weight
1 Healthcare 75.01%
2 Financials 4.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARYD
26
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$3.97M 1.44%
400,000
-200,000
-33% -$1.99M
CLDX icon
27
Celldex Therapeutics
CLDX
$2.78B
$3.86M 1.4%
100,000
+59,846
+149% +$2.61M
SNDX icon
28
Syndax Pharmaceuticals
SNDX
$1.88B
$3.83M 1.39%
+175,000
New +$3.23M
CBAY
29
DELISTED
Cymabay Therapeutics
CBAY
$3.79M 1.38%
+1,122,244
New +$4.26M
RCKT icon
30
Rocket Pharmaceuticals
RCKT
$358M
$3.6M 1.31%
165,000
+84,772
+106% +$2.31M
CRIS icon
31
Curis
CRIS
$9.1M
$3.09M 1.12%
1,625
+187
+13% +$445K
OBIO icon
32
Orchestra BioMed
OBIO
$218M
$3M 1.09%
300,000
– –
GRNA
33
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
$2.98M 1.08%
300,000
– –
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.93M 1.07%
20,000
-7,500
-27% -$1.16M
MSAC
35
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$2.92M 1.06%
300,000
– –
PRCT icon
36
Procept Biorobotics
PRCT
$999M
$2.5M 0.91%
100,000
+21,466
+27% +$794K
SNCE
37
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.87M 0.68%
7,500
– –
CVAC
38
CALL
DELISTED
CureVac
CVAC
$1.72M 0.62%
+50,000
New +$2.01M
TVTX icon
39
Travere Therapeutics
TVTX
$5.27B
$1.55M 0.56%
50,000
-150,000
-75% -$4.22M
BGMS
40
Bio Green Med Solution Inc
BGMS
$4.83M
$1.55M 0.56%
111
– –
ARKG icon
41
CALL
ARK Genomic Revolution ETF
ARKG
$1.55B
$1.53M 0.56%
+25,000
New +$1.73M
NTLA icon
42
Intellia Therapeutics
NTLA
$1.55B
$1.18M 0.43%
10,000
-5,000
-33% -$626K
SEER icon
43
CALL
Seer Inc
SEER
$113M
$1.14M 0.41%
50,000
– –
INO icon
44
CALL
Inovio Pharmaceuticals
INO
$83.9M
$998K 0.36%
+16,667
New +$1.34M
RCOR
45
DELISTED
Renovacor, Inc.
RCOR
$963K 0.35%
125,000
+10,000
+9% +$82.6K
IMTXW
46
DELISTED
Immatics N.V. Warrants
IMTXW
$834K 0.3%
190,000
– –
HYPR icon
47
Hyperfine
HYPR
$94.7M
$552K 0.2%
+76,162
New +$603K
RFL icon
48
PUT
Rafael Holdings
RFL
$109M
$516K 0.19%
102,617
– –
LIAN
49
DELISTED
LianBio American Depositary Shares
LIAN
$446K 0.16%
+72,406
New +$827K
ALDX icon
50
Aldeyra Therapeutics
ALDX
$93.5M
$403K 0.15%
100,759
-97,000
-49% -$740K
1
2
3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return

Affinity Asset Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Affinity Asset Advisors held 87 positions worth $275M, down 30% from $396M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Affinity Asset Advisors withdrew a net $91.5M in Q4 2021, closing 32 positions and reducing 10 holdings. Its most notable exit was Ocular Therapeutix, an estimated $7.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 56% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Protagonist Therapeutics worth $8.25M.

  • Affinity Asset Advisors's largest Q4 2021 buy was Protagonist Therapeutics: 241,119 shares worth $8.25M.
  • Affinity Asset Advisors added most to SpringWorks Therapeutics in Q4 2021, an estimated $11.4M increase.
  • Affinity Asset Advisors's biggest Q4 2021 reduction was BridgeBio Pharma, cutting an estimated $6.79M.
  • Affinity Asset Advisors fully exited Ocular Therapeutix in Q4 2021, selling an estimated $7.5M.
  • Affinity Asset Advisors's ten largest holdings make up 44% of its $275M portfolio in Q4 2021.
  • Affinity Asset Advisors opened 14 new positions and closed 32 in Q4 2021.
  • Affinity Asset Advisors's portfolio value fell 30% quarter-over-quarter to $275M.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.